Cloudbreak Pharma achieved its primary endpoint in Phase 2 for eye disease candidate CBT-004, an eye drop formulation. Encouraged by this mid-stage success, the company plans to advance CBT-004 into Phase 3 trials and engage with the FDA to define regulatory pathways toward approval, marking a significant milestone for its ophthalmology portfolio.